Scarica l'app Stockscreener
1.39
0.71%
-0.01
Dopo l'orario di chiusura:
1.40
0.01
+0.72%
Precedente Chiudi:
$1.40
Aprire:
$1.41
Volume 24 ore:
45,407
Relative Volume:
0.36
Capitalizzazione di mercato:
$99.77M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-23.63%
1M Prestazione:
-21.47%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.33
$1.44
Intervallo di 1 settimana:
$1.30
$1.7999
Portata 52W:
$1.30
$2.87
Citius Oncology Inc Stock (CTOR) Company Profile
Nome
Citius Oncology Inc
Settore
Industria
Telefono
(347) 627-0058
Indirizzo
420 LEXINGTON AVE,, NEW YORK
Citius Oncology Inc Borsa (CTOR) Ultime notizie
Citius Oncology (NASDAQ:CTOR) Stock Quotes, Forecast and News Summary - Benzinga
CTMX stock rated an Overweight by Piper Sandler - Knox Daily
CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Investor’s Delight: Cytek BioSciences Inc (CTKB) Closes Strong at 5.19, Up 1.96 - The Dwinnex
Cytek BioSciences Inc (CTKB)’s stock performance: a year in review - US Post News
Check Out Citius Pharmaceuticals Inc (CTXR)’s Trade Data Rather Than the Analysts’ Views - SETE News
CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News
Ciena Stock Goes to Buy From Sell at Citi. Here’s Why. - Barron's
Closing Strong: Citius Oncology Inc. (CTOR) Ends at 1.60, Down -4.19 from Last Close - The Dwinnex
XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World
CTOR stock touches 52-week low at $1.51 amid market challenges - Investing.com Canada
CitiusTech to pursue acquisitions, shifts hiring strategy on GenAI push - TechCircle
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Kilgore News Herald
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - Nasdaq
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering - Quantisnow
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
A stock that deserves closer examination: Citius Oncology Inc. (CTOR) - US Post News
Daily Market Movement: Citius Oncology Inc. (CTOR)’s financial ratios: A comprehensive overview - The Dwinnex
CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com
Citius Oncology Inc. (CTOR) requires closer examination - US Post News
Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton - TipRanks
CTOR’s Market Whiplash: -81.72% YTD Decline, -82.47% Plunge in 30 Days - The InvestChronicle
Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.00, Reflecting a -11.11 Downturn - The Dwinnex
Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com Australia
Citius Oncology Inc. completes strategic acquisition - Investing.com
Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com UK
Citius Pharma finalizes $675M oncology unit spinoff - NJBIZ
Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.47, Reflecting a -22.81 Downturn - The Dwinnex
Citius merges oncology subsidiary with TenX Keane - Yahoo Finance
Citius merges oncology subsidiary with TenX Keane - Pharmaceutical Technology
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology - citybiz
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - Kilgore News Herald
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Yahoo Finance
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Kilgore News Herald
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - Quantisnow
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - StockTitan
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - ForexTV.com
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - StockTitan
TenX Keane addresses trading halt, continues toward combination closing - TipRanks
New Ontak on track as Citius wins FDA’s nod for Lymphir in CTCL - BioWorld Online
US FDA approves Citius' therapy for rare blood cancer - Reuters.com
Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma - PR Newswire
Biotech Alert: Searches spiking for these stocks today - TipRanks
Citius Pharmaceuticals Advances Oncology Spinoff Through Merger with TenX Keane - Vancity Buzz
Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology - Nasdaq
Citius Pharma secures majority in TenX merger deal - Investing.com India
Citius Pharma secures majority in TenX merger deal By Investing.com - Investing.com Australia
Citius Pharma secures majority in TenX merger deal By Investing.com - Investing.com Canada
Citius Oncology Inc Azioni (CTOR) Dati Finanziari
Non sono disponibili dati finanziari per Citius Oncology Inc (CTOR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):